Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2021 1
2022 7
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Sworder BJ, et al. Among authors: hanoun c. Cancer Cell. 2023 Jan 9;41(1):210-225.e5. doi: 10.1016/j.ccell.2022.12.005. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584673 Free PMC article.
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Fante MA, Schroers R, Bayir L, Borchmann P, Buecklein V, Hasenkamp J, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P. Bethge WA, et al. Among authors: hanoun c. Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209. Blood. 2022. PMID: 35316325 Free article.
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: hanoun c. Blood. 2023 Jun 22;141(25):3055-3064. doi: 10.1182/blood.2022018558. Blood. 2023. PMID: 37001036 Free PMC article.
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
Hirmas N, Hamacher R, Sraieb M, Ingenwerth M, Kessler L, Pabst KM, Barbato F, Lueckerath K, Kasper S, Nader M, Schildhaus HU, Kesch C, von Tresckow B, Hanoun C, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Niedergethmann M, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: hanoun c. J Nucl Med. 2023 May;64(5):711-716. doi: 10.2967/jnumed.122.264689. Epub 2022 Dec 29. J Nucl Med. 2023. PMID: 36581374 Review.
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients.
Ferrández MC, Golla SSV, Eertink JJ, de Vries BM, Lugtenburg PJ, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, Kurch L, Hüttmann A, Hanoun C, Dührsen U, de Vet HCW; PETRA; Zijlstra JM, Boellaard R. Ferrández MC, et al. Among authors: hanoun c. Sci Rep. 2023 Aug 12;13(1):13111. doi: 10.1038/s41598-023-40218-1. Sci Rep. 2023. PMID: 37573446 Free PMC article.
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy.
Voltin CA, Gödel P, Beckmann L, Heger JM, Kobe C, Kutsch N, Borchmann P, Dietlein M, Herrmann K, Stelljes M, Rahbar K, Lenz G, Reinhardt HC, Teichert M, Noppeney R, Albring JC, Seifert R, von Tresckow B, Flossdorf S, Hanoun C. Voltin CA, et al. Among authors: hanoun c. Hemasphere. 2023 Jan 6;7(1):e817. doi: 10.1097/HS9.0000000000000817. eCollection 2023 Jan. Hemasphere. 2023. PMID: 36698613 Free PMC article.
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Voltin CA, Paccagnella A, Winkelmann M, Heger JM, Casadei B, Beckmann L, Herrmann K, Dekorsy FJ, Kutsch N, Borchmann P, Fanti S, Kunz WG, Subklewe M, Kobe C, Zinzani PL, Stelljes M, Roth KS, Drzezga A, Noppeney R, Rahbar K, Reinhardt HC, von Tresckow B, Seifert R, Albring JC, Blumenberg V, Farolfi A, Flossdorf S, Gödel P, Hanoun C. Voltin CA, et al. Among authors: hanoun c. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1361-1370. doi: 10.1007/s00259-023-06554-0. Epub 2023 Dec 20. Eur J Nucl Med Mol Imaging. 2024. PMID: 38114616 Free PMC article.
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Wiegers SE, Pieplenbosch S, Chamuleau MED, Lugtenburg PJ, de Jong D, Ylstra B, Mendeville M, Dührsen U, Hanoun C, Hüttmann A, Richter J, Klapper W, Jauw YWS, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: hanoun c. Blood Adv. 2023 Jan 24;7(2):214-223. doi: 10.1182/bloodadvances.2022008629. Blood Adv. 2023. PMID: 36306337 Free PMC article.
15 results